338.99
+15.99(+4.95%)
Currency In USD
Address
Four Tower Bridge
West Conshohocken, PA 19428
United States of America
Phone
267 824 2827
Sector
Healthcare
Industry
Biotechnology
Employees
376
First IPO Date
February 06, 2007
| Name | Title | Pay | Year Born |
| Mr. William J. Sibold | Chief Executive Officer, President & Director | 1.67M | 1966 |
| Ms. Carole Huntsman | Chief Commercial Officer | 94,001 | 1965 |
| Dr. Rebecca A. Taub M.D. | Founder, Chief Medical Officer, President of Research & Development and Director | 928,108 | 1952 |
| Mr. Mark Underwood | Senior Vice President of Business Planning & Operations | 0 | N/A |
| Mr. Ronald Filippo | Chief Information Officer | 0 | N/A |
| Mr. Edward Chiang | Senior Vice President of Clinical & Technical Operations | 0 | N/A |
| Ms. Mardi C. Dier | Chief Financial Officer & Senior Vice President | 0 | 1964 |
| Mr. Clint Wallace | Chief Human Resources Officer | 0 | N/A |
| Ms. Tina E. Ventura | Chief Investor Relations Officer | 0 | N/A |
| Ms. Shannon Kelley | Chief Compliance Office & General Counsel | 0 | N/A |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.